La Roche-Posay Effaclar Acne Serum with Salicylic Acid and Niacinamide for Oily and Acne Prone Skin 30 ml
19.00 JOD
La Roche-Posay Effaclar Acne Serum with Salicylic Acid and Niacinamide for Oily and Acne Prone Skin 30 ml
This lightweight salicylic acid acne treatment serum clears acne blemishes and helps prevent new breakouts, while also visibly reducing pores, fine lines, and post-acne marks.
Add to cart
Buy Now
About the Product
La Roche Posay Effaclar serum is a concentrate of exfoliating acids combined with soothing niacinamide, that targets blackheads, pimples, marks, and visible pores. This no-rinse formula leaves the skin refined and purified. The first ultra sensorial La Roche-Posay care to combine such a high concentration of synergic actives: 3 keratolytic acids to reduce imperfections and marks + niacinamide & Thermal spring water for a soothing, anti-redness effect and anti-recurrence proven efficacy. Specifically adapted and well-tolerated for acne-prone skin. Non-comedogenic. Tested on acne-prone skin. Avoid eye area. In contact with eyes, rinse thoroughly. Use in association with a daily photo-protection product (SPF > 15). Do not apply on open scars.
Key Benefits
- Formulated for adult acne
- Scientifically proven to help visibly reduce imperfections, fine lines wrinkles.
- Perfect balance between peeling and soothing actions,
How to Use
Apply to the whole face in the evening, after cleansing the skin with Effaclar Purifying Foaming gel.
Ingredients
aqua/water/eau, alcohol denat., propanediol, glycolic acid, niacinamide, dimethyl isosorbide, pentylene glycol, salicylic acid, sodium hydroxide, peg-60 hydrogenated castor oil, hydroxyethylpiperazine ethan sulfonic acid, citric acid, peg-30 glyceryl cocoate, capryloyl salicylic acid, biosaccharide gum-1, maltodextrin, phytic acid, polyquaternium-10, parfum/fragrance.
(*) The list of ingredients may be subject to change. We recommend that you refer to the ingredients directly on the product packaging before use.
| Size |
|---|
Reviews
There are no reviews yet.